A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma
Conditions
Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype · Astrocytoma, Grade III
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Northwestern Memorial Hospital, Chicago, Illinois, United States
New York University Langone Medical Center, New York, New York, United States
David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York, New York, United States
Baylor Scott & White Research Institute, Dallas, Texas, United States
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
South Texas Accelerated Research Therapeutics (START), San Antonio, Texas, United States
Huntsman Cancer Institute, Salt Lake City, Utah, United States
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
Hospital Universitario Vall d'Hebron, Barcelona, Spain
Hospital Universitario Donostia, Donostia / San Sebastian, Spain
Clinica Universidad de Navarra (CUN), Madrid, Spain
South Texas Accelerated Research Therapeutics (START), Madrid, Spain
Hospital Universitario 12 de Octubre, Madrid, Spain
Clinica Universidad de Navarra (CUN), Pamplona, Spain
Hospital Clinico Universitario de Valencia, Valencia, Spain
Universitaetsspital Zuerich, Zurich, Switzerland
Study leads
Study Director
Debiopharm International SA